All In Biotech

Drug Trial Radar · NCT06567015

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Sep 17, 2024

Primary completion

Nov 20, 2027

Study completion Jul 2030

Sponsor

Lead sponsor
Pierre Fabre MedicamentIndustry
Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • STX-241Drug

    Film-coated tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Part 1 and Part 2: Safety: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.Time frame: Screening to Safety Follow-up (30 days post last dose)
  2. Part 1 and Part 2: Tolerability: Incidence of TEAEs/SAEs leading to STX-241 dose reductions, interruptions or discontinuations.Time frame: Screening to Safety Follow-up (30 days post last dose)
  3. Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From first STX-241 intake until 28 days post first dose (28 days post first dose)
  4. Part 1: Optimal Biologically Active Dose (OBD)Time frame: From the first STX-241 intake up to 24 months
  5. Part 2: Recommended Phase II Dose (RP2D) of STX-241Time frame: From the first STX-241 intake up to 24 months
  6. Part 2: cORR (Confirmed Overall Response Rate) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per investigator.Time frame: Up to 24 months

Locations

18 sites in 7 countries. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)

    Nashville, Tennessee · Recruiting

  • Oncology Consultants (OC) - Texas Medical Center - Cancer Center

    Houston, Texas · Recruiting

  • Shanghai East Hospital, Tongji University

    Shanghai, China · Recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • CHU Hôpital de la Timone

    Marseille, France · Recruiting

  • Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau

    Saint-Herblain, France · Recruiting

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France · Recruiting

  • Gustave Roussy

    Villejuif, France · Recruiting

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Netherlands Cancer Institute

    Amsterdam, Netherlands · Recruiting

  • Hospital Quironsalud Barcelona

    Barcelona, Spain · Recruiting

  • Vall d'Hebron Institut d'Oncologia

    Barcelona, Spain · Recruiting

  • Hospital San Pedro

    Logroño, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Centro Intergral Oncologico Clara Campal (CIOCC) (START Madrid)

    Madrid, Spain · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.